VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

Robert L. Kirkman, MD
Published: Tuesday, Jun 24, 2014

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Two phase I trials are underway, looking at ONT-380 in combination with T-DM1 and in combination with capecitabine and trastuzumab.

A phase I trial with ONT-380 has been evaluated in this population of patients as well as a few patients with HER2-positive gastric cancer, Kirkman says. This analysis showed that ONT-380 is well tolerated and EGFR-related side effects were not observed. In a highly-pretreated population of patients with HER2-positive breast cancer, ONT-380 elicited a clinical benefit rate of 27%.

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Two phase I trials are underway, looking at ONT-380 in combination with T-DM1 and in combination with capecitabine and trastuzumab.

A phase I trial with ONT-380 has been evaluated in this population of patients as well as a few patients with HER2-positive gastric cancer, Kirkman says. This analysis showed that ONT-380 is well tolerated and EGFR-related side effects were not observed. In a highly-pretreated population of patients with HER2-positive breast cancer, ONT-380 elicited a clinical benefit rate of 27%.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x